Anterior Uveitis Treatment Market to Witness Excellent Growth by 2026 | Bausch &
Posted by Andre on November 26th, 2019
A new research study from “Data Bridge Market Research” with title Anterior Uveitis Treatment Market Insights 2019, Global Analysis and Forecast to 2026 provides an in-depth assessment of the Anterior Uveitis Treatment Market including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Some of the leading key players profiled in this study: Bausch & Lomb Incorporated, Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., EyeGate, Clearside Biomedical, Aldeyra Therapeutics, Aciont Inc., Sirion Therapeutics, Inc., EyePoint Pharmaceuticals, UAB Health System.
Global anterior uveitis treatment market is set to witness a substantial CAGR of 5.55% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017
Market Definition: Global Anterior Uveitis Treatment Market
Anterior uveitis is a condition which causes inflammation in the middle layer of the eyes. This disease can cause glaucoma, retinal edema and cataract which can further damage the eyes permanent and vision loss as well. Some of the common symptoms of this condition are red & sore eyes, blurred vision, small pupil and light sensitivity
Key Market Competitors:
Few of the major competitors currently working in the global anterior uveitis treatment market are Bausch & Lomb Incorporated, Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., EyeGate, Clearside Biomedical, Aldeyra Therapeutics, Aciont Inc., Sirion Therapeutics, Inc., EyePoint Pharmaceuticals, UAB Health System and others
Key Developments in the Market:
In July 2019, Aldeyra Therapeutics, Inc. announced the results from the noninfectious anterior uveitis SOLACE Trial. The results of the SOLACE Trial shows the ability of the reproxalap to treat ocular inflammation, and also demonstrated highly statistically significant immune-modulating activity in the Phase 3 ALLEVIATE Trial and Phase 2b Dry Eye Disease trial. The company is planning to develop in ocular programs in allergic conjunctivitis, dry eye disease and other
In March 2018, pSivida Corp. announced the acquisition of Icon Bioscience Inc and said that they will rebrand as EyePoint Pharmaceuticals. This rebranding will help the company to change from a research and development company to a biopharmaceutical company. This acquisition will help company to strengthen their position in the market. The company also partnered with two finance companies, EW Healthcare Partners and SWK Holdings Corporation, to fund the commercial development of Dexycu and Durasert
Global anterior uveitis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of anterior uveitis treatment market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa
Some of the key questions answered in this report:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research
Like it? Share it!
About the AuthorAndre
Joined: August 28th, 2019
Articles Posted: 300
More by this author